Last reviewed · How we verify

NCT06953180

Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction

Recruiting now Last updated 11 July 2025
What this trial tests

trial testing Genetic: DNA analysis in Cardiovascular Diseases (CVD) in 6,720 participants. Currently enrolling.

Timeline
3 March 2025
Primary endpoint
1 January 2026
31 December 2026

Quick facts

Lead sponsorAsfendiyarov Kazakh National Medical University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment6,720
Start date3 March 2025
Primary completion1 January 2026
Estimated completion31 December 2026
Sites1 location across Kazakhstan

Drugs / interventions tested

Conditions studied

Sponsor

Asfendiyarov Kazakh National Medical University

Who can join

Adults 18 to 69, any sex, with Cardiovascular Diseases (CVD) or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Vaccination Attitudes in the Adult Population of Kazakhstan: A Nationally Representative Cross-Sectional Study.
    Ismoldayev Y, Ibrayeva A, Izdenov A, Lee S, et al · · 2026 · PMID 42042829 · DOI 10.3390/vaccines14040353

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases (CVD)

Currently open trials in the same condition.

Other Asfendiyarov Kazakh National Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06953180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing